Taken together, these results demonstrate that BEX2 is overexpressed in lung adenocarcinoma and is associated with poor prognosis in lymph node metastasis-free patients and clinical stage (I + II) patients. This evidence concerns the gene BEX2 and lung adenocarcinoma.